Ua ʻae ʻia ʻo Semeglutide API o Shenzhen JYMed e ka pūʻulu mua o NMPA kūloko a hoʻopaʻa inoa ʻia ma US FDA (DMF No. 036009) me ke kūlana "A".

I Mei 2022, ua waiho ʻo Shenzhen JYMed Technology Co., Ltd. (i kapa ʻia ʻo JYMed peptide) i kahi noi no ka hoʻopaʻa inoa ʻana i ka API semaglutide i ka US Food and Drug Administration (FDA) (helu helu inoa DMF: 036009), Ua hala. ka loiloi pono, a ʻo ke kūlana o kēia manawa ʻo "A".Ua lilo ʻo JYMed peptide i kekahi o ka pūʻulu mua o nā mea hana API semaglutide ma Kina e hala i ka loiloi US FDA.

Ma Pepeluali 16, 2023, ua hoʻolaha ka pūnaewele mana o ka Drug Evaluation Center o ka State Drug Administration i ka API semaglutide [helu inoa inoa: Y20230000037] i hoʻopaʻa inoa ʻia a hoʻolaha ʻia e Hubei JXBio Co., Ltd., kahi hui o JYMed peptide, ua loaʻa. ʻae ʻia.Ua lilo ʻo JYMed peptide i kekahi o nā mea hana lāʻau lapaʻau maka mua i ʻae ʻia ka noi kūʻai aku no kēia huahana ma Kina.

E pili ana i ka semaglutide
ʻO Semaglutide kahi agonist receptor GLP-1 i hoʻomohala ʻia e Novo Nordisk (Novo Nordisk).Hiki i ka lāʻau lapaʻau ke hoʻonui i ka glucose metabolism ma o ka hoʻoulu ʻana i nā cell pancreatic β e huna i ka insulin, a ke kāohi i ka huna ʻana o ka glucagon mai nā pūnaewele pancreatic α e hōʻemi i ka hoʻokē ʻai a me ke kō koko postprandial.Eia kekahi, hoʻemi ia i ka ʻai ʻana i ka meaʻai ma ka hoʻēmi ʻana i ka ʻai a me ka hoʻolohi ʻana i ka ʻai ʻana i loko o ka ʻōpū, ʻo ia ka mea e hōʻemi ai i ka momona o ke kino a kōkua i ka pohō kaumaha.
1. ʻIke kumu
Mai kahi hiʻohiʻona o ka manaʻo, i hoʻohālikelike ʻia me ka liraglutide, ʻo ka hoʻololi nui loa o ka semaglutide ʻo ia ʻelua mau AEEA i hoʻohui ʻia i ke kaulahao ʻaoʻao o lysine, a ua hoʻololi ʻia ka waikawa palmitic e ka octadecanedioic acid.Ua hoʻololi ʻia ʻo Alanine e Aib, ka mea i hoʻonui nui i ka hapalua o ke ola o semaglutide.

Kiʻi Kūlana o semaglutide

2. Nā hōʻailona
1) Hiki i ka Semaglutide ke hoʻemi i ka hopena o nā hanana cardiovascular i nā maʻi me T2D.
2) Hoʻohaʻahaʻa ʻo Semaglutide i ke kō koko ma ka hoʻoulu ʻana i ka huna ʻana o ka insulin a me ka hoʻohaʻahaʻa ʻana i ka huna ʻana o ka glucagon.Ke kiʻekiʻe ke kō koko, hoʻoulu ʻia ka huna ʻana o ka insulin a pale ʻia ka huna ʻana o ka glucagon.
3) Novo Nordisk PIONEER ho'āʻo hoʻokolohua hōʻike i ka hoʻoponopono waha o semaglutide 1mg, 0.5mg iʻoi aku ka maikaʻi o ka hypoglycemic a me nā hopena kaumaha ma mua o Trulicity (dulaglutide) 1.5mg, 0.75mg.
3) ʻO ka semaglutide waha ke kāleka pu o Novo Nordisk.Hiki i ka hoʻokele waha i hoʻokahi lā ke hoʻopau i ka pilikia a me ka hoʻomāinoino noʻonoʻo i hoʻokumu ʻia e ka injection, a ʻoi aku ka maikaʻi ma mua o ka liraglutide (injection hoʻokahi i ka pule).ʻO nā hopena hypoglycemic a me ke kaumaha o nā lāʻau lapaʻau nui e like me , empagliflozin (SGLT-2) a me sitagliptin (DPP-4) he mea hoihoi loa ia i nā maʻi a me nā kauka.Ke hoʻohālikelike ʻia me nā ʻōnaehana injection, e hoʻomaikaʻi maikaʻi ʻia nā ʻano o ka waha i ka maʻalahi o ka noi ʻana o ka semaglutide.

3. Hōʻuluʻulu manaʻo
Ma muli o kāna hana maikaʻi loa i ka hypoglycemic, ke kaumaha o ke kaumaha, ka palekana a me nā pono cardiovascular i lilo ai ka semaglutide i kahi kūlana "hōkū hou" me ka manaʻo nui o ka mākeke.